Professor Luke O’Neill holds the Chair of Biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. His research is in the area of the molecular basis to inflammation with a particular focus on innate immunity, Toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation. In 2016 he was named by Clarivates/Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in Immunology. He is co-founder of 2 Spin-out companies - Opsona Therapeutics and Inflazome, which is developing new treatments for inflammatory diseases. He was elected a Fellow of the Royal Society in 2016.
« Go Back